Stay updated on PF-06650833/PF-06700841/PF-06826647 in Hidradenitis Suppurativa Clinical Trial
Sign up to get notified when there's something new on the PF-06650833/PF-06700841/PF-06826647 in Hidradenitis Suppurativa Clinical Trial page.

Latest updates to the PF-06650833/PF-06700841/PF-06826647 in Hidradenitis Suppurativa Clinical Trial page
- ChecktodayChange DetectedExpanded the Locations section to list study sites across multiple US states (Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana, Kentucky, Massachusetts, Michigan, Minnesota, Missouri, Nebraska, Nevada, New York, Oklahoma, Pennsylvania, Tennessee, Texas, Utah, Virginia, Washington) and international sites in Australia (Australian Capital Territory, New South Wales, Queensland, Victoria) and Canada (Ontario, Quebec). The HHS Vulnerability Disclosure link was removed.SummaryDifference2%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check29 days agoChange DetectedThe Publications section now notes that publications are automatically filled from PubMed, and the revision tag has been updated from v3.2.0 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check36 days agoChange DetectedRemoved the general government funding/status banner from the page. The study details, eligibility criteria, and primary outcomes remain unchanged.SummaryDifference0.2%

- Check58 days agoChange DetectedNo significant changes detected between the two screenshots of the Study Details page; only minor cosmetic formatting adjustments are visible. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check79 days agoChange DetectedAdded a government funding lapse notice and a v3.2.0 version tag, replacing the prior v3.1.0.SummaryDifference2%

- Check86 days agoChange DetectedUpdated version to v3.1.0 and removed several drug-safety topic items (Drug Safety, Counterfeit Drugs, Pharmaceutical Preparations, Substandard Drugs) while retaining an older revision in deletions (v3.0.2).SummaryDifference0.2%

Stay in the know with updates to PF-06650833/PF-06700841/PF-06826647 in Hidradenitis Suppurativa Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PF-06650833/PF-06700841/PF-06826647 in Hidradenitis Suppurativa Clinical Trial page.